This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Resources - Articles

Return to Sender – Clinical Trial Returns

Article courtesy of ICT (International Clinical Trials) – Oct 2014

Trial planning inevitably focuses on the set-up and timely delivery of studies – and less on later logistics such as the return of unused drugs. But neglecting this issue can lead to scope creep and unexpected costs, which is why early dialogue and decisions on returns are essential.

In recent years, the pharmaceutical industry has witnessed tremendous change in the way it is expected to deliver new drugs to market. This has been driven by several factors.

The industry has faced head-on the prospect of ‘the patent cliff’, losing about $290 billion in revenue from branded prescription medications going off-patent. At the same time,drug development timelines are under constant attack, with speed to market paramount to success. As such, innovation and cost-effi ciency is crucial ….

Read More:

October 12, 2015


PCI Pharma Services Completes Expansion of its Specialty Drug Product Capabilities at Rockford, IL Site

Increases Capacity at State-of-the-Art Facility in Response to Growing Market Needs PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma Services (PCI), a leading pharmaceutical and... View Article

PCI Unveils Clinical Center of Excellence

Expanded Clinical Services Facility in Rockford, IL to Support Growth and Flexibility with 30,000 additional sq ft We have officially... View Article

x